The DOI matches its Crossref record; 247 of the 247 references it cites were found in a registry or an index.
Selective inhibitors of picornavirus replication
Abstract
Picornaviruses cover a large family of pathogens that have a major impact on human but also on veterinary health. Although most infections in man subside mildly or asymptomatically, picornaviruses can also be responsible for severe, potentially life‐threatening disease. To date, no therapy has been approved for the treatment of picornavirus infections. However, efforts to develop an antiviral that is effective in treating picornavirus‐associated diseases are ongoing. In 2007, Schering‐Plough, under license of ViroPharma, completed a phase II clinical trial with Pleconaril, a drug that was originally rejected by the FDA after a New Drug Application in 2001. Rupintrivir, a rhinovirus protease inhibitor developed at Pfizer, reached clinical trials but was recently halted from further development. Finally, Biota's HRV drug BTA‐798 is scheduled for phase II trials in 2008. Several key steps in the picornaviral replication cycle, involving structural as well as non‐structural proteins, have been identified as valuable targets for inhibition. The current review aims to highlight the most important developments during the past decades in the search for antivirals against picornaviruses. © 2008 Wiley Periodicals, Inc. Med Res Rev, 28, No. 6, 823–884, 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–247 of 247
Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers
PHILLPOTTS, R. J., Higgins, P. G., Willman, J. S., Tyrrell, D. A. J., & Lenox-Smith, I. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.4.403 · Cited by 44
Structure Determination of Antiviral Compound SCH 38057 Complexed with Human Rhinovirus 14
Zhang, A., Nanni, R. G., Li, T., Arnold, G. F., Oren, D. A., Jacobo‐Molina, A., Williams, R. L., Kamer, G., Rubenstein, D. A., Li, Y., et al. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1206 · Cited by 43
Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors
Dragovich, P. S., Zhou, R., Webber, S. E., et al. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00587-9 · Cited by 42
Failure of oral 4′, 6-dichloroflavan to protect against rhinovirus infection in man
PHILLPOTTS, R. J., Wallace, J. G., Tyrrell, D. A. J., Freestone, D. S., & Shepherd, W. M. (1983) · Archives of Virology · doi:10.1007/bf01314131 · Cited by 41
Salvati, A. L., Dominicis, A. D., Tait, S., Canitano, A., Lahm, A., & Fiore, L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2233-2243.2004 · Cited by 40
Richer, J. K., Hunt, W. G., Sakanari, J. A., & Grieve, R. B. (1993) · Experimental Parasitology · doi:10.1006/expr.1993.1027 · Cited by 38
Requirements for RNA Replication of a Poliovirus Replicon by Coxsackievirus B3 RNA Polymerase
Bell, Y. C., Semler, B. L., & Ehrenfeld, E. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9413-9421.1999 · Cited by 38
Wang, W., Lee, W.-M., Mosser, A. G., & Rueckert, R. R. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1210-1218.1998 · Cited by 38
What does the molecular structure of viruses tell us about viral functions?
Rossmann, M. G., & Reuckert, R. R. (1987) · PubMed · Cited by 37
Johnson, T., Hua, Y., Luu, H. T., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010435c · Cited by 37
Rozhon, E. J., Cox, S., Buontempo, P. J., O’Connell, J. F., Slater, W., Martino, J. D., Schwartz, J., Miller, G., Arnold, E., Zhang, A., et al. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90064-p · Cited by 37
Dual Inhibition of Human Rhinovirus 2A and 3C Proteases by Homophthalimides
Wang, Q. M., Johnson, R. B., Jungheim, L. N., Cohen, J. D., & Villarreal, E. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.916 · Cited by 37
Intranasal chalcone, Ro 09–0410, as prophylaxis against rhinovirus infection in human volunteers
Al‐Nakib, W., Higgins, P. G., Barrow, I., Tyrrel, D. A. J., Lenox-Smith, I., & Ishitsuka, H. (1987) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/20.6.887 · Cited by 36
Inhibitors of 3C Cysteine Proteinases from Picornaviridae
Lall, M. S., Jain, R., & Vederas, J. C. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387836 · Cited by 36
Equine rhinitis B virus: a new serotype
Huang, J., Ficorilli, N., Hartley, C. A., et al. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-11-2641 · Cited by 35
Lall, M. S., Karvellas, C. J., & Vederas, J. C. (1999) · Organic Letters · doi:10.1021/ol990148r · Cited by 34
Dimova, S. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00363-6 · Cited by 34
Conti, C., Genovese, D., Santoro, R., et al. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.3.460 · Cited by 34
Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies
Cox, S., Buontempo, P. J., Wright-Minogue, J., et al. (1996) · Antiviral Research · doi:10.1016/0166-3542(95)00979-5 · Cited by 33
Beneficial effect of new thiol protease inhibitors, epoxide derivatives, on dystrophic mice
Komatsu, K., Inazuki, K., Hosoya, J., et al. (1986) · Experimental Neurology · doi:10.1016/0014-4886(86)90022-1 · Cited by 32
Synthesis of new 3-methylthio-5-aryl-4-isothiazolecarbonitriles with broad antiviral spectrum
Cutrı̀, C. C. C., Garozzo, A., SIRACUSA, M. A., Castro, A., Tempera, G., Sarva, M. C., & Guerrera, F. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00072-4 · Cited by 32
Use of WIN 51711 to Prevent Echovirus Type 9-Induced Paralysis in Suckling Mice
McKinlay, M. A., Frank, J. A., Benziger, D. P., & Steinberg, B. A. (1986) · The Journal of Infectious Diseases · doi:10.1093/infdis/154.4.676 · Cited by 32
Lee, W.-M., & Wang, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6235-6244.2003 · Cited by 32
Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers
Zerial, A., Werner, G. H., PHILLPOTTS, R. J., Willman, J. S., Higgins, P. G., & Tyrrell, D. A. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.27.5.846 · Cited by 31
KADAM, S. K., Poddig, J. B., HUMPHREY, P. E., Karwowski, J. P., JACKSON, M., TENNENT, S., FUNG, L., Hochlowski, J. E., Rasmussen, R. R., & McAlpine, J. B. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.836 · Cited by 31
Zhang, K. E., Hee, B., LEE, C. A., et al. (2001) · PubMed · Cited by 30
Venkatraman, S., Kong, J.-S., Nimkar, S., et al. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00049-9 · Cited by 29
Hershenson, M. B., & Johnston, S. L. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200609-1387ed · Cited by 28
Anti-rhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivatives
Garozzo, A., Cutrì, C. C. C., Castro, A., Tempera, G., Guerrera, F., Sarva, M. C., & GEREMIA, E. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00072-3 · Cited by 26
Al‐Nakib, W., Willman, J. S., Higgins, P. G., Tyrrell, D. A. J., Shepherd, W. M., & Freestone, D. S. (1987) · Archives of Virology · doi:10.1007/bf01317482 · Cited by 25
Dragovich, P. S., Webber, S. E., Prins, T. J., et al. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00368-6 · Cited by 25
Novel Triterpene Sulfates from Fusarium compactum Using a Rhinovirus 3C Protease Inhibitor Screen.
BRILL, G. M., Kati, W. M., Montgomery, D., Karwowski, J. P., HUMPHREY, P. E., JACKSON, M., Clement, J. J., KADAM, S. K., CHEN, R. H., & McAlpine, J. B. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.541 · Cited by 24
Jubelt, B., Wilson, A. K., Kopka, S., Guidinger, P. L., & McKinlay, M. A. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/159.5.866 · Cited by 24
S-Nitrosothiols as novel, reversible inhibitors of human rhinovirus 3C protease
Xian, M., Wang, Q. M., Chen, X., Wang, K., & Wang, P. G. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00420-0 · Cited by 23
Hill, R. D., & Vederas, J. C. (1999) · The Journal of Organic Chemistry · doi:10.1021/jo9915123 · Cited by 22
Chern, J., Chang, C., Tai, C., Lee, Y., Lee, C.-C., Kang, I., Lee, C.-Y., & Shih, S. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.069 · Cited by 21
Inhibition of 3C Protease from Human Rhinovirus Strain 1B by Peptidyl Bromomethylketonehydrazides
Kati, W. M., Sham, H. L., McCall, J., Montgomery, D., Wang, G. T., Rosenbrook, W., Miesbauer, L. R., BUKO, A. M., & Norbeck, D. W. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.1038 · Cited by 21
McKendrick, J. E., Frormann, S., Luo, C., Semchuck, P., Vederas, J. C., & Malcolm, B. A. (1998) · International Journal of Mass Spectrometry · doi:10.1016/s1387-3806(98)14022-8 · Cited by 19
WIN 54954 treatment of mice infected with a diabetogenic strain of group B coxsackievirus
See, D. M., & Tilles, J. G. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.8.1593 · Cited by 18
Higgins, P. G., Barrow, G. I., Al‐Nakib, W., Tyrrell, D. A. J., DeLong, D. C., & Lenox-Smith, I. (1988) · Antiviral Research · doi:10.1016/0166-3542(88)90022-8 · Cited by 17
In vitro inhibitory effects of dual combinations of picornavirus replication inhibitors.
Nikolaeva, L., & As, G. (1999) · PubMed · Cited by 17
Picornavirus Structure Overview
Rossmann, M. G. (2014) · ASM Press eBooks · doi:10.1128/9781555817916.ch3 · Cited by 16
Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors
Webber, S. E., Marakovits, J. T., Dragovich, P. S., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00542-x · Cited by 16
Inhibitor of NFκB Alpha is a Host Sensor of Coxsackievirus Infection
Saura, M., Lizarbe, T. R., Rama-Pacheco, C., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.5.3918 · Cited by 13
In vivo efficacy of SDZ 35-682, a new picornavirus capsid-binding agent
Rosenwirth, B., Kis, Z. L., & Eggers, H. J. (1995) · Antiviral Research · doi:10.1016/0166-3542(94)00065-g · Cited by 11
Antipicornavirus activity of some diaryl methanes and aralkylaminopyridines
Kenny, M. T., Dulworth, J. K., Bargar, T. M., et al. (1987) · Antiviral Research · doi:10.1016/0166-3542(87)90024-6 · Cited by 9
6-(3,4-Dichlorophenoxy)-3-(ethylthio)-2-pyridincarbonitrile inhibits poliovirus uncoating
González, M. E., Almela, M. J., Yacout, M., et al. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1259 · Cited by 3
Cited by
Colunga Biancatelli, R. M. L., Berrill, M., Catravas, J. D., & Marik, P. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01451 · Cited by 512
Mastrangelo, E., Pezzullo, M., De Burghgraeve, T., Kaptein, S., Pastorino, B., Dallmeier, K., de Lamballerie, X., Neyts, J., Hanson, A. M., Frick, D. N., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks147 · Cited by 414
Self-citationThe role of viruses in acute exacerbations of asthma
Jackson, D. J., & Johnston, S. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.021 · Cited by 351
Viral infections in type 1 diabetes mellitus — why the β cells?
Op de Beeck, A., & Eizirik, D. L. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.30 · Cited by 291
The ABCs of Rhinoviruses, Wheezing, and Asthma
Gern, J. E. (2010) · Journal of Virology · doi:10.1128/jvi.02290-09 · Cited by 263
Metadata
- Authors
- De Palma, A. M., Vliegen, I., De Clercq, E., & Neyts, J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2008-04
- Volume
- 28
- Issue
- 6
- Pages
- 823-884
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2133646471
- Cited by
- 259
- References
- 247
- FWCI
- 14.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.